Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Neurological manifestations in COVID-19 survivors: Observations in one of the largest only COVID-19 centers in México.
Infectious Disease
P5 - Poster Session 5 (11:45 AM-12:45 PM)
13-003

Since the beginning of the pandemic in 2019 of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing human coronavirus disease 2019 (COVID-19) persistent symptoms are being reported among COVID-19 survivors, our objective is to report neurological manifestations in hospitalized COVID-19 survivors.

 

To describe the neurological complications in COVID-19 survivors 3 months after hospital discharge

We report the neurological sequelae observed in a cohort of 238 patients who were admitted in a single center with acute respiratory distress syndrome (ARDS) due to COVID-19, 3 months after their hospital discharge, a complete neurological examination and MOCA cognitive screening test was performed by 2 neurologists in Mexico City from August 31, 2020 to January 8, 2021. 

In all patients, reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays of nasopharyngeal samples were positive for SARSCoV-2. The mean age of the patients was 51 years, 97 patients (68.3%) needed mechanical ventilatory support, 52% with a periphery oxygen saturation at admission of less than 60%, 10.6% were health care workers, 8 patients has had previous neurologic disorders. The main sequels observed were sensory motor neuropathy (66.4%), myopathic pain (43. 9%), cognitive complains (59.7%) with an average MOCA of 25.5 (46.6%). 5 patients had ischemic cerebral vascular disease, 5 patients had seizures, 108 (45.6%) affective symptoms, 52.2% patients with a RANKIN less than 2.

It is crucial a multidisciplinary long term follow up of the patients who survived the COVID -19 to recognize the different range of neurological sequelae; this in order to provide better clinical prognoses and to optimize the algorithms of treatment
Authors/Disclosures
Monica Saray Rodriguez Rodríguez, Sr., MD (Instituto Nacional de Enfermedades Respiratorias ICV)
PRESENTER
Dr. Rodríguez has nothing to disclose.
Raul Anwar Garcia Santos, MD Dr. Santos has nothing to disclose.
Diana Sarai Lopez Gonzalez (Instituto Nacional de Enfermedades Respiratorias) Dr. Lopez Gonzalez has nothing to disclose.